BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Merck
Dow
Cipla
Cantor Fitzgerald
Chinese Patent Office
Fish and Richardson
Argus Health
McKesson
Chubb

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,550,440

« Back to Dashboard

Summary for Patent: 7,550,440
Title:Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Abstract: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
Inventor(s): Manetta; Vincent (Bordentown, NJ), Watkins; Gary R. (Piscataway, NJ)
Assignee: Galderma S.A. (Cham, CH)
Application Number:11/255,910
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 7,550,440

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,550,440

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France03 05048Apr 24, 2003

Non-Orange Book US Patents Family Members for Patent 7,550,440

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,598,129 Topical application of ivermectin for the treatment of dermatological conditions/afflictions ➤ Subscribe
8,080,530 Topical application of ivermectin for the treatment of dermatological conditions/afflictions ➤ Subscribe
8,093,219 Topical application of ivermectin for the treatment of dermatological conditions/afflictions ➤ Subscribe
8,624,678 Output stage of a power amplifier having a switched-bulk biasing and adaptive biasing ➤ Subscribe
8,470,788 Topical application of ivermectin for the treatment of dermatological conditions/afflictions ➤ Subscribe
8,415,311 Topical application of ivermectin for the treatment of dermatological conditions/afflictions ➤ Subscribe
8,815,816 Topical application of ivermectin for the treatment of dermatological conditions/afflictions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,550,440

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1620113 ➤ Subscribe
Russian Federation 2350333 ➤ Subscribe
Russian Federation 2005136438 ➤ Subscribe
Portugal 1620113 ➤ Subscribe
Poland 378932 ➤ Subscribe
Mexico PA05011208 ➤ Subscribe
Luxembourg 92915 ➤ Subscribe
South Korea 101291824 ➤ Subscribe
South Korea 20120062028 ➤ Subscribe
South Korea 101187231 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
US Department of Justice
Deloitte
Accenture
Covington
Teva
Boehringer Ingelheim
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot